Gilead CEO says coronavirus hopeful remdesivir will be 'affordable,' but it could still rake in revenue

30th March 2020 Uncategorised 0

Will Gilead Sciences make a fortune out of remdesivir if the antiviral proves itself against the novel coronavirus? CEO Daniel O’Day said the Big Biotech will “work to ensure affordability and access so that remdesivir is available to patients with the greatest need” if it’s approved. But with a large pool of potential patients, there’s plenty of room for sales.

More: Gilead CEO says coronavirus hopeful remdesivir will be 'affordable,' but it could still rake in revenue
Source: fierce